A5102993560- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- SARS-CoV-2 and COVID-19 Research
- Glycosylation and Glycoproteins Research
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Lung Cancer Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Treatment and Research
- Cancer therapeutics and mechanisms
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Cancer Research and Treatments
- Vaccine Coverage and Hesitancy
Olivia Newton-John Cancer Wellness & Research Centre
2013-2024
Austin Health
2009-2024
Austin Hospital
2006-2024
The University of Melbourne
2009-2024
Cedars-Sinai Medical Center
2022-2023
Footscray Hospital
2019-2023
Northern Health
2012-2017
St Vincent's Hospital
2016
Northern Hospital
1984-2016
The University of Notre Dame Australia
2016
Abstract Purpose: Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous pulsed mannan-MUC1 fusion protein (MFP) to treat patients advanced malignancy. Experimental Design: Eligible had adenocarcinoma expressing MUC1, were of performance status 0 1, no autoimmune disease. Patients underwent leukapheresis generate by culture ex vivo granulocyte macrophage colony-stimulating factor and interleukin 4 5 days....
Abstract Purpose: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). Patients Methods: The single-arm CO40151 phase Ib study (NCT03800836), the signal-seeking cohort of IPATunity130 (NCT03337724), randomized III IPATunity170 trial (NCT04177108) enrolled patients with previously untreated mTNBC. Triplet comprised intravenous atezolizumab...
Intravaginal testosterone (IVT) is a potential treatment of vulvovaginal atrophy (VVA) associated with aromatase inhibitor (AI) use.To investigate the effects IVT on sexual satisfaction, vaginal symptoms, and urinary incontinence (UI) AI use.Double-blind, randomized, placebo-controlled trial.Academic clinical research center.Postmenopausal women taking an VVA symptoms.IVT cream (300 μg per dose) or identical placebo, self-administered daily for 2 weeks then thrice weekly 24 weeks.The primary...
Abstract Purpose: Recent randomized trials in advanced TNBC have demonstrated improved efficacy with the addition of atezo to 1L nab-PAC patients (pts) PD-L1+ tumors (IMpassion130 [Schmid 2018]), and oral AKT inhibitor IPAT PAC, particularly pts PIK3CA/AKT1/PTEN-altered (LOTUS [Kim 2017]). Loss PTEN, a negative regulator AKT, has emerged as potential mechanism for resistance checkpoint therapy; inhibiting PI3K/AKT pathway led reversal T-cell-mediated immunotherapy [Peng 2016]. We report...
Background Cancer-Testis Antigens (CTAs) are immunogenic proteins that poor prognostic markers in non-small cell lung cancer (NSCLC). We investigated expression of CTAs NSCLC and their association with response to chemotherapy, genetic mutations survival. Methods studied 199 patients pathological N2 treated neoadjuvant chemotherapy (NAC; n = 94), post-operative observation (n 49), adjuvant 47) or unknown 9). Immunohistochemistry for NY-ESO-1, MAGE-A MAGE-C1 was performed. Clinicopathological...
Abstract Context Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of has been reported to have on composition preclinical observational studies, but evidence from double-blind randomized controlled trials limited. Objective To assess the effect denosumab parameters. Methods In a prespecified secondary...
<h3>Background</h3> Mucin 1 antigen, highly expressed by epithelial ovarian cancer (EOC), is a potential target for immunotherapy. A previous successful phase trial was conducted in patients with adenocarcinoma who were injected Cvac, autologous monocyte-derived dendritic cells (DCs) incubated mannosylated mucin protein (M-FP). The present study 2 of Cvac advanced EOC. <h3>Methods</h3> Eligible had EOC progressive disease, defined as an increase CA125 ≥ 25% 1 month. primary endpoint...
Summary Background We investigated whether metformin prevents tamoxifen‐induced endometrial changes and insulin resistance ( IR ) after a diagnosis of breast cancer. Methods This was single‐centre, randomized, double‐blind, placebo‐controlled, parallel group trial. Postmenopausal women with hormone receptor‐positive cancer taking tamoxifen were randomly allocated to 850 mg or identical placebo, twice daily, for 52 weeks. Outcome measures included double thickness ET measured by transvaginal...
PURPOSE Suppression of ovarian function and aromatase inhibition (AI) increases disease-free survival in premenopausal women with estrogen receptor (ER)–positive early-stage breast cancer but accelerates bone loss. We therefore hypothesized that suppressing remodeling using denosumab (DMAB) would prevent loss these women. METHODS In a 12-month double-blind randomized trial, 68 ER-positive commencing suppression AI were randomly assigned to 60 mg DMAB (n = 34) or placebo (PBO; n once every 6...
BACKGROUND Information on the effect of chemotherapy in a group patients with poor prognosis, performance status small cell lung carcinoma (SCLC) is scarce. A randomized study comparing single-agent carboplatin combination this largely unreported population SCLC was undertaken. METHODS One hundred nineteen were allocated to four cycles either cyclophosphamide, doxorubicin, and vincristine (CAV) or carboplatin. Patients had Karnofsky score ≤ 50 and/or prognostic indicative 1-year survival...
Abstract Concurrent chemoradiotherapy ( CCRT ) has become the standard of care for patients with unresectable stage III non–small cell lung cancer NSCLC ). The comparative merits two widely used regimens: carboplatin/paclitaxel PC and cisplatin/etoposide PE ), each concurrent radiotherapy, remain largely undefined. Records consecutive treated or ≥60 Gy chest radiotherapy between 2000 2011 were reviewed outcomes toxicity. Survival was estimated using Kaplan–Meier method Cox modeling Wald...
8514 Background: Early phase trials of anti-programmed death 1 (PD-1) antibodies have demonstrated important responses in malignant mesothelioma (MM). Expression the ligand, PD-L1, is a potential biomarker for PD-1 directed therapy use and expressed significant proportion MM. We present results cohort treated with inhibitory assessed PD-L1 expression. Methods: Patients (pts) unresectable pleural or peritoneal mm anti-PD-1 were included. Data was collected retrospectively. Radiological...
Abstract Background The safety of a third dose SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown. Methods We compared symptoms following vaccine after the second IBD. Results study group included 594 (70% female, 58% BNT162b2). Overall, 41% reported dose. Symptom frequency and severity were lower relative to for every organ system, except gastrointestinal which marginally worse. Conclusion are generally similar or milder than most systems.
Aim The potential beneficial interaction between erlotinib and chemotherapy may require sequencing or pharmacodynamic separation. aim of this study was to evaluate the efficacy tolerance sequential gemcitabine versus monotherapy as first-line therapy in elderly ECOG PS-2 patients with advanced non-small cell lung carcinoma. Methods primary objective multicenter randomized Phase II progression-free survival (PFS). Secondary objectives were overall response rate (ORR), disease control rate,...
This study determined the efficacy and safety of a modified FOLFOX regimen that improved patient convenience without compromising oxaliplatin dose intensity. A total 62 patients with previously untreated metastatic colorectal cancer were enrolled to receive, entirely as outpatients, 2-weekly cycles 100 mg m−2 i.v. over 2 h, together leucovorin 400 5-fluorouracil (5-FU) m−2, bolus, followed by 46-h infusion 5-FU at 2.4 g m−2. Treatment was given until progression or unmanageable toxicity. In...